C. Everett Koop
Keine laufenden Positionen mehr
Profil
C.
Everett Koop has been a Director of Biopure Corp.
since December 1990 and is a Director of drkoop.com and Biomedics.
From September 1994 to November 1997, he was Chairman of Patient Education Media, Inc. Dr. Koop served as the Surgeon General of the United States from 1981 to 1989 and was Senior Scholar of the C.
Everett Koop Institute at Dartmouth College.
He received an ScD degree from the Graduate School of the University of Pennsylvania, an MD degree from the Cornell University Medical College and an AB degree from Dartmouth College.
Ehemalige bekannte Positionen von C. Everett Koop
| Unternehmen | Position | Ende |
|---|---|---|
Biopure Corp.
 Biopure Corp. Pharmaceuticals: MajorHealth Technology Biopure Corp. developed, manufactured and marketed oxygen therapeutics, a new class of pharmaceuticals that are administered intravenously to increase oxygen transport to the body's tissues. The company used patented and proprietary technology to develop and manufacture two products: Hemopure for human use, and Oxyglobin for veterinary use. It has developed Hemopure for the treatment of patients with cardiovascular ischemia. Oxyglobin, its veterinary product treated anemia in dogs, is the only oxygen therapeutic approved by the U.S. Food and Drug Administration and the European Commission. Biopure was founded in 1984 and was headquartered in Cambridge, MA. | Direktor/Vorstandsmitglied | - |
Ausbildung von C. Everett Koop
| Cornell University | Doctorate Degree |
| Dartmouth College | Undergraduate Degree |
| University of Pennsylvania | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 1 |
|---|---|
Biopure Corp.
Biopure Corp. Pharmaceuticals: MajorHealth Technology Biopure Corp. developed, manufactured and marketed oxygen therapeutics, a new class of pharmaceuticals that are administered intravenously to increase oxygen transport to the body's tissues. The company used patented and proprietary technology to develop and manufacture two products: Hemopure for human use, and Oxyglobin for veterinary use. It has developed Hemopure for the treatment of patients with cardiovascular ischemia. Oxyglobin, its veterinary product treated anemia in dogs, is the only oxygen therapeutic approved by the U.S. Food and Drug Administration and the European Commission. Biopure was founded in 1984 and was headquartered in Cambridge, MA. | Health Technology |
